The new device offers real-time insights into cycle health, fertility and hormonal balance with precision once only found in clinics
Mira, a San Francisco-based hormonal health company, has unveiled Ultra4, the first at-home hormone monitor capable of tracking four key reproductive hormones, FSH, LH, E3G and PdG, with clinical-level precision. Using a single wand and a 16-minute test, Ultra4 delivers a comprehensive hormonal profile directly to users, a big step forward in cycle health monitoring.
“When we launched Mira, it was with a single hormone and a single goal: help women understand their fertility better,” said Sylvia Kang, CEO and Co-founder of Mira. “But users kept asking harder questions—about irregular cycles, missed ovulation, egg quality, hormonal balance. Ultra4 is our answer to those questions. It reflects everything we’ve learned in the past seven years from listening to our community.”
Mira began in 2018 with an ovulation tracker designed to measure luteinizing hormone (LH), giving users a better way to pinpoint their fertile window. However, many people face irregular cycles, PCOS, or fertility struggles that can’t be explained by one hormone alone. With Ultra4, Mira has expanded its capabilities to measure follicle-stimulating hormone, luteinizing hormone, estrone-3-glucuronide and pregnanediol glucuronide simultaneously, offering a detailed hormonal picture across the entire cycle.
By tracking multiple hormones together, the device makes it possible to assess ovulation timing and strength, detect subtle shifts that point to imbalances and follow longer-term changes in reproductive health. Mira notes this can help users monitor follicle development early in the cycle, understand egg health and ovarian reserve, evaluate how well hormones work together and create a personalized hormonal baseline over time. For people managing complex fertility journeys, approaching perimenopause, or just trying to understand their cycles better, this represents an improved level of at-home information.
Ultra4 uses fluorescent technology, the same method employed in clinical laboratories, which Mira says provides up to seven times the accuracy of other consumer fertility trackers. The system’s sensitivity allows it to pick up on minor hormonal changes that standard tests often miss. Unlike traditional devices, users are not restricted to specific testing windows; they can test on any day of their cycle, or even multiple times per day, with the guidance of Mira’s AI-powered app. The app adapts as it gathers data, learning each individual’s hormonal patterns and building what Mira calls a “Hormonal Fingerprint” to flag irregularities or early signs of change.
Ultra4 also represents the company’s broader vision to address what Kang describes as a persistent blind spot in women’s health: the lack of accessible, continuous hormone data. Mira has plans to expand into monitoring additional markers, like cortisol and testosterone and to introduce wearable devices that can track multiple hormones in real time.
“Real hormonal health is more than a peak or a surge,” Kang explained. “Our vision is to give people a complete understanding of their hormonal landscape across every stage of life.”
